TP53 and acute myeloid leukemia: [107] Two parallel French and US-based phase Ib/II trials are evaluating this combination in HMA-naïve, TP53-mutated patients with high-risk MDS, CMML, or AML, and preliminary results have been highly promising with ORR between 54 and 88%, in a very high-risk elderly population, generally characterized by complex karyotype and unresponsiveness to standard treatments [108,109].